Day: December 22, 2020

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat Still’s disease has been accepted by the United States Food and Drug Administration (FDA) and is now open. CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). The first study will be a global multicenter Phase 1b clinical trial in adult onset Still’s disease and is planned to start in the first quarter of 2021. Initial data is expected in the second quarter of 2021.“Adult onset Still’s disease (AOSD) is a rare inflammatory disease resulting in joint damage, high fever...

Kanton Basel-Stadt übernimmt die Anteile des Kantons Basel-LandschaftDer Kanton Basel-Stadt übernimmt die Anteile des Kantons Basel-Landschaft an der MCH Group AG. Im Rahmen des im Frühjahr 2020 angekündigten Ausstiegs hat der Kanton Basel-Landschaft vereinbarungsgemäss seine bisher gehaltenen 471’250 Aktien dem Partnerkanton zum Kauf angedient, der dieses Angebot angenommen hat.Mit der Übernahme des Anteils des Kantons Basel-Landschaft hält der Kanton Basel-Stadt nun 4’492’447 Aktien der MCH Group AG, was einem Anteil von 30.21 % entspricht. Die an der MCH Group AG beteiligten öffentlich-rechtlichen Körperschaften – der Kanton Basel-Stadt sowie der Kanton und die Stadt Zürich – halten insgesamt 33.34 %.News online Kontakt für die Medien:MCH Group AGCorporate CommunicationsChristian Jecker+41 58 206 22 52christian.j...

Le canton de Bâle-Ville reprend les parts du canton de Bâle-CampagneLe canton de Bâle-Ville reprend les parts du canton de Bâle-Campagne dans MCH Group SA. Dans le cadre du désengagement annoncé au printemps 2020, le canton de Bâle-Campagne a proposé ses 471 250 actions détenues à ce jour au canton partenaire, qui a accepté cette offre.Avec la reprise des parts du canton de Bâle-Campagne, le canton de Bâle-Ville détient désormais 4 492 447 actions de MCH Group SA, ce qui correspond à une participation de 30,21 %. Les collectivités de droit public participant à MCH Group SA – le canton de Bâle-Ville ainsi que le canton et la ville de Zurich – en détiennent au total 33,34 %.News onlineContact pour les médiasMCH Group SACorporate CommunicationsChristian Jecker+41 58 206 22 52christian.jecker@mch-group.comwww.mch-group.com

Canton Basel-Stadt acquiring the shares of Canton Basel-LandschaftCanton Basel-Stadt is acquiring the shares of Canton Basel-Landschaft in MCH Group Ltd. Following the announcement of its withdrawal in spring 2020, Canton Basel-Landschaft has now, as agreed, tendered the 471,250 shares it has held to date to its partner canton, which has accepted the offer.With the acquisition of Canton Basel-Landschaft’s stake, Canton Basel-Stadt now holds 4,492,447 shares in MCH Group Ltd., corresponding to a 30.21% stake. The public-sector entities with shares in MCH Group Ltd. – Canton Basel-Stadt and the Canton and City of Zurich – together have an overall stake of 33.34%.News onlineMedia contact:MCH Group AGCorporate CommunicationsChristian Jecker+41 58 206 22 52christian.jecker@mch-group.comwww.mch-group.com

22 December 2020, Road Town, Tortola, BVIReferring to the Company’s press release dated 11 December 2020, EPH European Property Holdings Ltd. (the “Company”) announces the successful settlement, listing and trading of 4,435,000 new ordinary shares against payment of the subscription price.The Company’s issued share capital now consists of 14,409,022 ordinary shares, of which all are duly authorized, validly issued, fully paid and non-assessable. As a result, unissued (authorized) shares comprise of 6’590’978 ordinary shares without par value and 1,000,000 series A non-voting preferred shares without par value.As a result of the transaction, the shareholder structure and free float of EPH has changed. The Company could successfully attract additional investors resulting in free float of shareholders holding below 10%...

VANCOUVER, British Columbia, Dec. 22, 2020 (GLOBE NEWSWIRE) — Neptune Digital Assets Corp. (TSX-V:DASH) (OTC:NPPTF) (FSE:1NW) (“Neptune” or the “Company“) is pleased to announce that it has released its August 31, 2020 audited financial statements and management, discussion and analysis.Below are a number of financial highlights pertaining to the August 31, 2020 year end and for the period subsequent to year end and up to the date of this News Release.Over the last two years the Company has been aggressively cutting costs and as such has achieved an annual positive net comprehensive income for its first time being $657,249 or $0.01 per share for the 12 months ended August 31, 2020.Assuming crypto prices stay constant or climb higher, we expect these earnings to improve significantly into 2021 and beyond with operating...

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of approximately 5.1 million shares of common stock at a price of $1.60 per share.The estimated net proceeds to PAVmed from the Offering are expected to be approximately $7.4 million after deducting the placement agents’ fees and other estimated offering expenses. PAVmed plans to use the net proceeds for working capital, general corporate purposes, and to repay a portion of certain of the Company’s outstanding convertible notes.Maxim Group LLC acted as the lead placement agent and Lake Street Capital Markets LLC acted as co-placement agent in connection...

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Dune Acquisition Corporation (the “Company”) announced today the closing of its upsized initial public offering of 17,250,000 units, including 2,250,000 issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $172,250,000. The units are listed on the Nasdaq Capital Market (the “Nasdaq”) and commenced trading under the ticker symbol “DUNEU” on December 18, 2020. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are...

Saint-Herblain (France), December 22, 2020 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting (EGM) held on December 22, 2020.  Due to the COVID-19 pandemic, this EGM was held as a closed meeting without the physical presence of shareholders.  Full voting results will be available on the Company’s website within fifteen days.Among the resolutions approved during the EGM were delegations for the management board to increase the share capital and/or to issue financial instruments.Valneva called the EGM in order to obtain the necessary authorizations to allow the Company to prepare for a potential listing and public offering...

Saint-Herblain (France), 22 décembre 2020 – Valneva SE (“Valneva” ou “le Groupe”), société spécialisée dans les vaccins contre des maladies générant d’importants besoins médicaux, a annoncé aujourd’hui que toutes les résolutions recommandées par le directoire ont été approuvées par ses actionnaires lors de l’Assemblée Générale Extraordinaire qui s’est tenue le 22 décembre 2020. En raison de la pandémie de COVID-19, l’assemblée s’est tenue à huis clos sans la présence physique des actionnaires. Les résultats détaillés des votes de cette assemblée seront disponibles sur le site internet de la société dans un délai maximal de quinze jours.Parmi les résolutions approuvées lors de l’Assemblée Générale Extraordinaire figurent des délégations consenties au directoire pour augmenter le capital social de la société ou émettre certains instruments...